Get your free ETF data sample from our comprehensive offerings. Start your free trial→

Help us improve your experience. Please confirm your investor type:

ETF What's Up

Don’t Miss a Move in the ETF Market

Sign up and keep track of everything that moved the ETF industry this week. From new launches to regulatory shifts across the Atlantic.

›ETF Issuers›VIRTUS Investment Partners›BBC

BBC

Virtus LifeSci Biotech Clinical Trials ETF

Passive ETF Equity Theme: Tomorrow's Treatments

The BBC Exchange Traded Fund (ETF) is provided by VIRTUS Investment Partners. It is built to track an index: LifeSci Biotechnology Clinical Trials Index. The BBC ETF provides physical exposure, so by buying it you actually own parts of all the 125 underlying holdings. This share class generates a stream of income by distributing dividends.

$49.74

+$0.071 (+0.14%) yesterday

1:30 PM 07/27/26 Closed

1D price range

$49.59$50.69

52W price range

$21.09$54.85

YTD Perf.

+28.33%

YTD Flows

Annualized volatility

Fund AuM

€41M

Share class AuM

€41M

TTM Yield

Tracking Error

Tracking Difference

Characteristics

ISIN

US26923G3011

TER

0.65%

Inception date

12/16/2014

Issuer

VIRTUS Investment Partners

Benchmark

LifeSci Biotechnology Clinical Trials Index

Replication method

Dividend policy

Distributing

Compare similar ETFs

ETF Name	1w perf.
SBIO ALPS Medical Breakthroughs ETF	-2.18%
XPH State Street SPDR S&P Pharmaceuticals ETF	-0.98%
PSCH Invesco S&P SmallCap Health Care ETF	-1.29%
LFSC F/m Emerald Life Sciences Innovation ETF	-1.39%
CURE Global X S&P Biotech ETF	-2.59%
XBI State Street SPDR S&P Biotech ETF	-2.47%
PTH Invesco DWA Healthcare Momentum ETF	-1.59%
AAKG ARK Genomic Revolution UCITS ETF	-5.10%
ARKG ARK Genomic Revolution ETF	-5.17%
XHE State Street SPDR S&P Health Care Equipment ETF	-2.33%
IBRN iShares Neuroscience and Healthcare ETF	-0.47%
GNOM Global X Genomics & Biotechnology ETF	-1.78%
GNOG Global X Genomics & Biotechnology UCITS ETF	-1.77%
GNMX Corgi Genomics & Precision Medicine ETF	-1.74%
FMED Fidelity Disruptive Medicine ETF	-1.68%

API

PerformanceDec 31, 2025 - Jul 24, 2026

Flows

Join for free to unlock

Sector exposures

Data as of 06/30/26

Healthcare

95.19%

Unavailable

4.81%

Latest BBC news

No content available for this fund

FAQ about BBC

BBC is a Passive ETF. This ETF provides exposure to Equally Weighted US Equities.

BBC tracks the LifeSci Biotechnology Clinical Trials Total Return Index - USD, through a full replication replication method.

BBC carries a total expense ratio (TER) of 0.65%, indicating the annual cost for holding the fund.

BBC was introduced to the market on December 16, 2014. It trades on United States

Virtus LifeSci Biotech Clinical Trials ETF, BBC, is provided by VIRTUS Investment Partners. Learn more about VIRTUS Investment Partners here.

BBC oversees €41M in assets as of July 24, 2026.

BBC follows a distributing dividend policy, meaning it pays out income to investors. As of July 24, 2026, its 12-month trailing yield was 1.32%.

As of June 30, 2026, BBC has significant geographic allocations in USA, Netherlands and Canada.

As of June 30, 2026, BBC focuses largely on Healthcare.

As of June 30, 2026, BBC holds 125 positions in its portfolio, with 14.01% of assets concentrated in its top 15 holdings.

As of June 30, 2026, BBC top three holdings include uniQure NV, REGENXBIO, Inc. and Apogee Therapeutics, Inc..

The base currency of BBC is USD.

Top 10 holdings

Data as of 06/30/26

uniQure NV

1.18%

REGENXBIO, Inc.

1.01%

Apogee Therapeutics, Inc.

0.99%

Monopar Therapeutics, Inc.

0.97%

Jade Biosciences, Inc.

0.94%

Aktis Oncology, Inc.

0.94%

MBX Biosciences, Inc.

0.94%

Biohaven Ltd.

0.90%

Cullinan Therapeutics, Inc.

0.89%

Kymera Therapeutics, Inc.

0.89%

Essentials

A forever free toolbox for fund selection, analysis, research, and ETF portfolio construction.

Essential free account includes:

More fund data
Compare up to 3 funds
More screener filters
Edit screener columns from 100+ metrics
Watchlists for saving your research
Portfolio construction and analysis
Personal dashboard for live monitoring

About Trackinsight

Since our founding in 2016, we have been at the forefront of the industry, delivering accessible, comprehensive, and reliable tools to support the evolving needs of investors.

Over the past decade, Trackinsight has expanded its operations across six countries, serving thousands of professional investors. We’ve consistently innovated to provide cutting-edge solutions that meet the changing demands of the ETF market.

In 2024, Kepler Cheuvreux, a leading independent European financial services firm, acquired a majority stake in Trackinsight, becoming the company's principal shareholder.

This strategic partnership solidifies Trackinsight's position as a premier provider of ETF selection and analysis tools, while strengthening Kepler Cheuvreux’s commitment to becoming a leading player in the ETF sector.

Together, we are committed to offering advanced services that empower professional investors, advisors, institutions, and issuers. This new step enables us to deliver even more comprehensive and innovative technological solutions, driving ETF investing to new heights.

More about Trackinsight

Don’t Miss a Move in the ETF Market

Virtus LifeSci Biotech Clinical Trials ETF

FAQ about BBC

Essentials

About Trackinsight

ETF TOOLS

PLATFORM

ETF NEWS & RESEARCH

PROFESSIONAL SOLUTIONS

SOLUTIONS FOR

CONTACT US